Bajaj Healthcare

Which are the latest news on Bajaj Healthcare?

Why is Bajaj Healthcare Ltd falling/rising?

As of 05-Sep, Bajaj Healthcare Ltd's stock price is Rs 321.50, down 1.67% and on a four-day decline totaling 3.19%. The stock has significantly underperformed year-to-date, with a 22.58% drop compared to the Sensex's 10.21% decline.

As of 05-Sep, Bajaj Healthcare Ltd's stock price is falling, currently at Rs 321.50, which reflects a decrease of Rs 5.45 or 1.67%. The stock has been on a downward trend, having lost value for the last four consecutive days, resulting in a total decline of 3.19% during this period. Additionally, the stock has underperformed compared to the sector by 0.82% today.<BR><BR>In terms of broader performance, Bajaj Healthcare has shown significant declines over various time frames, with a year-to-date drop of 22.58% and a one-year decrease of 24.72%. This contrasts sharply with the benchmark Sensex, which has only fallen by 10.21% year-to-date. The stock is also trading below its moving averages across multiple time frames, including the 5-day, 20-day, 50-day, 100-day, and 200-day averages, indicating a sustained bearish trend.<BR><BR>Despite a rise in investor participation, with delivery volume increasing by 59.75% against the 5-day average, the overall market sentiment appears negative, contributing to the stock's decline. The stock also reached an intraday low of Rs 320, further emphasizing its downward movement.

Who are in the management team of Bajaj Healthcare?

The management team of Bajaj Healthcare includes Sanjankumar R Bajaj (Chairman & Managing Director), Anil C Jain (Joint Managing Director), and several other directors, including independent and whole-time directors, who collectively guide the company's strategic direction and operations.

The management team of Bajaj Healthcare includes the following key members:<BR><BR>1. **Sanjankumar R Bajaj** - Chairman & Managing Director<BR>2. **Anil C Jain** - Joint Managing Director<BR>3. **Namrata S Bajaj** - Whole-time Director<BR>4. **Dhananjay S Halte** - Whole-time Director<BR>5. **Rupesh H Nikam** - Whole Time Director & CFO<BR>6. **Ram B Banarase** - Independent Director<BR>7. **Hemant R Karnik** - Independent Director<BR>8. **Aakashkumar Kesari** - Company Secretary<BR>9. **Avinash Dalal** - Independent Director<BR>10. **Loukik D Tipnis** - Independent Director<BR>11. **Luke Benedict Fernandez** - Independent Director<BR>12. **Kejal Shah** - Independent Director<BR>13. **Pakshal Jain** - Director<BR><BR>This team plays a crucial role in guiding the company's strategic direction and operations.

What does Bajaj Healthcare do?

Bajaj Healthcare Ltd. is a micro-cap bulk drug manufacturer in the Pharmaceuticals & Biotechnology industry, established in 1993 and publicly listed since 2005. As of June 2026, it reported net sales of ₹166 Cr and a net profit of ₹14 Cr, with a market cap of ₹1,121 Cr.

Overview: <BR>Bajaj Healthcare Ltd. is a bulk drug manufacturer operating in the Pharmaceuticals & Biotechnology industry and is categorized as a Micro Cap company.<BR><BR>History: <BR>Bajaj Healthcare was established in 1993 and became a public company in 2005. It listed its shares on the Indian stock exchanges in 2016. The most recent quarterly results reported net sales and net profit for June 2026.<BR><BR>Financial Snapshot: <BR>Net Sales: 166 Cr (Quarterly Results - Jun 2026) <BR>Net Profit: 14 Cr (Quarterly Results - Jun 2026) <BR>Market Cap: INR 1,121 Cr (Micro Cap) <BR><BR>Key Metrics: <BR>P/E: 20.00 <BR>Industry P/E: 37 <BR>Dividend Yield: 0.29% <BR>Debt-Equity: 0.46 <BR>Return on Equity: 11.49% <BR>Price to Book: 2.22 <BR><BR>Contact Details: <BR>Address: 602-606 Bhoomi Velocity Infote, Road No 23 Wagle Indl Estate Thane Maharashtra : 400604 <BR>Tel: 91-22-66177400/401 <BR>Email: investors@bajajhealth.com <BR>Website: http://www.bajajhealth.com

Who are the peers of the Bajaj Healthcare?

Bajaj Healthcare's peers include Fermenta Biotec, Sigachi Industries, Lincoln Pharma, and others, with varying management risk and growth ratings. Bajaj Healthcare has the lowest 1-year return at -21.10%, significantly underperforming compared to its peers.

Peers: Bajaj Healthcare's peers include Fermenta Biotec., Sigachi Indust., Lincoln Pharma., Themis Medicare, Kopran, Bharat Parenter., Wanbury, Anuh Pharma, Remus Pharma, and Accent Microcell.<BR><BR>Quality Snapshot: Excellent management risk is observed at Sigachi Indust., Lincoln Pharma., Anuh Pharma, and Remus Pharma, while Average management risk is found at Fermenta Biotec., Themis Medicare, Bajaj Healthcare, Kopran, Wanbury, and the rest. Below Average management risk is noted at Bharat Parenter. Growth is rated as Excellent for Sigachi Indust., Lincoln Pharma., and Anuh Pharma, while Average growth is seen at Wanbury and the rest. Below Average growth is present at Fermenta Biotec., Themis Medicare, Bajaj Healthcare, Kopran, Bharat Parenter., and the rest. Capital Structure is Excellent for Sigachi Indust., Lincoln Pharma., Anuh Pharma, and Remus Pharma, Good for Kopran, and Below Average for Fermenta Biotec., Themis Medicare, Bajaj Healthcare, Bharat Parenter., and Wanbury.<BR><BR>Return Snapshot: The peer with the highest 1-year return is Kopran at 40.77%, while Bajaj Healthcare has the lowest at -21.10%. Bajaj Healthcare's return is significantly lower than all its peers. Additionally, Wanbury and Anuh Pharma have negative six-month returns.

How big is Bajaj Healthcare?

As of 31st August, Bajaj Healthcare Ltd has a market capitalization of 1,121.00 Cr, with recent net sales of 627.82 Cr and a net profit of 17.63 Cr.

As of 31st August, Bajaj Healthcare Ltd has a market capitalization of 1,121.00 Cr, categorizing it as a Micro Cap company.<BR><BR>In the latest four quarters, Bajaj Healthcare reported Net Sales of 627.82 Cr and a Net Profit of 17.63 Cr.<BR><BR>The latest annual period for the balance sheet is March 2025, with Shareholder's Funds amounting to 466.16 Cr and Total Assets valued at 814.15 Cr.

Are Bajaj Healthcare Ltd latest results good or bad?

Bajaj Healthcare Ltd's latest results show a significant recovery in net profit and sales growth, indicating improved operational performance. However, concerns about long-term sales decline and profitability sustainability suggest caution in evaluating the company's overall health.

Bajaj Healthcare Ltd's latest results show a mixed picture. On one hand, the company reported a significant recovery in net profit, achieving ₹13.89 crores, which is a remarkable 171.54% increase quarter-on-quarter and a 14.13% increase year-on-year. This recovery follows a challenging previous quarter where the company posted a loss.<BR><BR>Net sales also grew, reaching ₹165.63 crores, marking an 8.21% increase from the previous quarter and an 11.28% increase year-on-year, which is the highest quarterly revenue in recent history. Additionally, operating margins improved to 17.36%, up from 14.82% in the prior quarter, indicating better cost management.<BR><BR>However, despite these positive developments, there are underlying concerns. The company has faced a long-term decline in sales and profitability, with a five-year annual sales decline of 1.44% and EBIT contraction of 8.46%. The current profitability, while improved, still raises questions about sustainability, especially given the volatility in quarterly earnings.<BR><BR>In summary, while the latest results indicate a recovery and improved operational metrics, the persistent structural challenges and historical performance issues suggest that caution is warranted when evaluating the overall health of Bajaj Healthcare Ltd.

Should I buy, sell or hold Bajaj Healthcare Ltd?

Is Bajaj Healthcare technically bullish or bearish?

As of December 1, 2025, Bajaj Healthcare's technical trend has shifted to a moderate bearish stance, indicated by bearish MACD, Bollinger Bands, and moving averages, despite a mildly bullish KST signal on the weekly chart.

As of 1 December 2025, the technical trend has changed from mildly bearish to bearish. The current technical stance for Bajaj Healthcare is bearish with a moderate strength. Key indicators driving this stance include the bearish MACD on the weekly chart, bearish Bollinger Bands on both weekly and monthly time frames, and a bearish moving average on the daily chart. The KST shows a mildly bullish signal on the weekly but remains mildly bearish on the monthly, indicating some divergence. Overall, the lack of strong signals from the RSI and Dow Theory further supports the bearish outlook.

How has been the historical performance of Bajaj Healthcare?

Bajaj Healthcare's historical performance has shown significant fluctuations, with net sales peaking at 645.80 Cr in Mar'23 but declining to 542.60 Cr by Mar'25, alongside decreases in profit metrics and cash flow, despite an increase in total assets. Overall, the company has faced both growth and challenges in its financial performance.

Answer:<BR>The historical performance of Bajaj Healthcare shows significant fluctuations in key financial metrics over the years.<BR><BR>Breakdown:<BR>Bajaj Healthcare's net sales have experienced variability, peaking at 645.80 Cr in Mar'23 before declining to 542.60 Cr in Mar'25. The total operating income followed a similar trend, with a high of 679.89 Cr in Mar'22 and a decrease to 542.60 Cr in Mar'25. Raw material costs rose from 291.33 Cr in Mar'19 to 307.11 Cr in Mar'25, while total expenditure, excluding depreciation, increased from 327.55 Cr in Mar'19 to 460.17 Cr in Mar'25. Operating profit (PBDIT) fluctuated, reaching a high of 143.23 Cr in Mar'21 but dropping to 101.83 Cr in Mar'25. Profit before tax saw a significant decline from 118.82 Cr in Mar'21 to 46.01 Cr in Mar'25, with profit after tax also decreasing from 83.11 Cr in Mar'21 to 42.93 Cr in Mar'25. The company's total assets increased from 342.95 Cr in Mar'20 to 814.15 Cr in Mar'25, while total liabilities rose from 182.57 Cr in Mar'21 to 272.27 Cr in Mar'25. Cash flow from operating activities showed a decline from 43.00 Cr in Mar'21 to 21.00 Cr in Mar'25, with net cash inflow remaining stable at 0.00 Cr in Mar'25. Overall, Bajaj Healthcare's financial performance reflects a mix of growth and challenges over the years.

Is Bajaj Healthcare overvalued or undervalued?

As of November 7, 2025, Bajaj Healthcare is considered overvalued with a PE ratio of 27.28, significantly higher than its peers like Cipla and Dr. Reddy's Labs, and has underperformed the Sensex with a year-to-date return of -24.7%.

As of 7 November 2025, Bajaj Healthcare's valuation grade has moved from fair to expensive, indicating a shift in its perceived market value. The company is currently overvalued based on its financial metrics. Key ratios include a PE ratio of 27.28, an EV to EBITDA of 18.91, and a PEG ratio of 0.83, which suggests that while the company is growing, its valuation may not be justified by its earnings growth prospects.<BR><BR>In comparison to its peers, Bajaj Healthcare's PE ratio is notably higher than Cipla's 22.33, which is rated attractive, and Dr. Reddy's Labs at 17.43, also attractive. This indicates that Bajaj Healthcare is trading at a premium relative to these competitors despite not offering a significantly better growth outlook. Additionally, the stock has underperformed against the Sensex in the year-to-date period, with a return of -24.7% compared to the Sensex's 6.50%, further reinforcing the notion that the stock may be overvalued in the current market environment.

Who are the top shareholders of the Bajaj Healthcare?

The top shareholders of Bajaj Healthcare include Sajankumar Rameshwarlal Bajaj with 37.59%, individual investors with 26.72%, and institutional investors, including mutual funds at 1.64% and foreign institutional investors at 1.05%. The largest public shareholder is Vanaja Sundar Iyer, holding 2.22% of the shares.

The top shareholders of Bajaj Healthcare include the promoters, with Sajankumar Rameshwarlal Bajaj holding the highest stake at 37.59%. Additionally, individual investors collectively own 26.72% of the shares. The company also has some institutional investment, with mutual funds holding 1.64% through one scheme and foreign institutional investors (FIIs) holding 1.05% across ten different entities. The highest public shareholder is Vanaja Sundar Iyer, who holds 2.22% of the shares.

When is the next results date for Bajaj Healthcare?

No Upcoming Board Meetings

What is the bonus history of the Bajaj Healthcare?

Bajaj Healthcare announced a 1:1 bonus issue on April 9, 2019, with a record date of April 10, 2019, granting shareholders one additional share for each share held.

Bajaj Healthcare has a bonus history that includes a 1:1 bonus issue announced on April 9, 2019. The record date for this bonus was April 10, 2019. This means that shareholders received one additional share for every share they held as of the record date.

Has Bajaj Healthcare declared dividend?

Yes, Bajaj Healthcare Ltd has declared a 20% dividend, amounting to ₹1 per share, with an ex-date of September 23, 2024. The company has shown strong total returns over various periods, including a 310.14% return over the last 5 years.

Bajaj Healthcare Ltd has declared a 20% dividend.<BR><BR>Dividend Details:<BR>- Percentage announced: 20%<BR>- Amount per share: 1 per share<BR>- Ex-date: 23 Sep 24<BR><BR>Dividend Yield: 0.19%.<BR><BR>Total Returns by Period:<BR>In the last 6 months, Bajaj Healthcare experienced a price return of 21.85%, with no dividend return, resulting in a total return of 21.85%.<BR><BR>Over the past year, the company saw a price return of 81.69% and a dividend return of 0.32%, leading to a total return of 82.01%.<BR><BR>In a 2-year period, the price return was 76.99%, with a dividend return of 0.64%, culminating in a total return of 77.63%.<BR><BR>For the 3-year period, the price return stood at 67.82%, while the dividend return was 1.26%, resulting in a total return of 69.08%.<BR><BR>In the 4-year timeframe, the price return was 36.62%, with a dividend return of 1.04%, leading to a total return of 37.66%.<BR><BR>Over the last 5 years, Bajaj Healthcare achieved a remarkable price return of 307.08% and a dividend return of 3.06%, resulting in a total return of 310.14%.<BR><BR>Overall, Bajaj Healthcare's dividend declaration reflects a commitment to returning value to shareholders, and the substantial total returns across various periods indicate strong performance and growth potential for the company.